A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Abstract

The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy.

References 68

1. 1.

   Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733..

   Not in our library10.1056/nejmoa2001017

2. 2.
   The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 · 2020

   No notice
3. 3.

   Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. 2020. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 32:107940..

   Not in our library10.1016/j.celrep.2020.107940

4. 4.

   Ziebuhr J, Siddell SG. 1999. Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab. J Virol 73:177–185..

   Not in our library10.1128/jvi.73.1.177-185.1999

5. 5.

   Gadlage MJ, Denison MR. 2010. Exchange of the coronavirus replicase polyprotein cleavage sites alters protease specificity and processing. J Virol 84:6894–6898..

   Not in our library10.1128/jvi.00752-10

6. 6.
   Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease · 2020

   No notice
7. 7.
   Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors · 2020

   No notice
8. 8.

   Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, et al. 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468..

   Not in our library10.1038/s41586-020-2286-9

9. 9.

   Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY, Lockner JW, Lou J, Marra MT, Mitchell LJ, Murray BW, Nieman JA, Noell S, Planken SP, Rowe T, Ryan K, Smith GJ, Solowiej JE, Steppan CM, Taggart B. 2020. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 63:12725–12747..

   Not in our library10.1021/acs.jmedchem.0c01063

10. 10.

    Yoshino R, Yasuo N, Sekijima M. 2020. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. Sci Rep 10:12493..

    Not in our library10.1038/s41598-020-69337-9

11. 11.

    Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J. 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30:678–692..

    Not in our library10.1038/s41422-020-0356-z

12. 12.

    Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, Duan Y, Yu J, Yang X, Yang X, Yang K, Liu X, Guddat LW, Xiao G, Zhang L, Yang H, Rao Z. 2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 27:529–532..

    Not in our library10.1038/s41594-020-0440-6

13. 13.

    Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. 2020. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289–293..

    Not in our library10.1038/s41586-020-2223-y

14. 14.

    Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond J, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Luthra SA, Ma C, Noell S, Obach RS, O’Brien MN, O’Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers T, Rossulek MI, Sathish JG, Steppan C, Ticehurst M, Updyke LW, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Anderson AS, Allerton C. 2020. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv.

    Not in our library10.1101/2020.09.12.293498

15. 15.

    Bossennec M, Di Roio A, Caux C, Ménétrier-Caux C. 2018. MDR1 in immunity: friend or foe? Oncoimmunology 7:e1499388-11..

    Not in our library10.1080/2162402x.2018.1499388

16. 16.

    Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. 2004. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48:1073–1081..

    Not in our library10.1128/aac.48.4.1073-1081.2004

17. 17.

    Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB. 2020. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383:590–592..

    Not in our library10.1056/nejmc2011400

18. 18.

    Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen H-L, Peiris M, Wu J. 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179..

    Not in our library10.1056/nejmc2001737

19. 19.

    Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl Hoagland SD, Møller R, Jordan TX, Oishi K, Panis Sachs MD, Wang TT, Schwartz RE, Lim JK, Albrecht RA, TenOever R. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036–1045.e9..

    Not in our library10.1016/j.cell.2020.04.026

20. 20.

    Shannon A, Le NT-T, Selisko B, Eydoux C, Alvarez K, Guillemot J-C, Decroly E, Peersen O, Ferron F, Canard B. 2020. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res 178:104793..

    Not in our library10.1016/j.antiviral.2020.104793

21. 21.

    Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, Du Plessis L, Pybus OG. 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5:1403–1407..

    Not in our library10.1038/s41564-020-0770-5

22. 22.
    Introductions and early spread of SARS-CoV-2 in the New York City area · 2020

    No notice
23. 23.

    Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. 2020. Spike mutation D614G alters SARS-CoV-2 fitness. Nature.

    Not in our library10.1038/s41586-020-2895-3

24. 24.
    SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo · 2020

    No notice
25. 25.

    Thornburg N, Bradford R, Rashid S, Flores B, Parker M, Tallon L, Sadzewicz L, Ott S, Vavikolanu K, Nadendla S, Sichtig H. 2020. Data from “FDA Database for Regulatory Grade Microbial Sequences (FDA-ARGOS): supporting development and validation of infectious disease Dx tests.”

    Not in our library

26. 26.

    Roder A, Banakis S, Johnson K, Khalfan M, Borenstein E, Samanovic M, Cornelius A, Herati R, Ulrich R, Fleming A, Kottkamp A, Raabe V, Mulligan MJ, Gresham D, Ghedin E. 2020. Data from “SARS-CoV-2 sequences from COVID19 patients in New York.” GenBank https://www.ncbi.nlm.nih.gov/nuccore/MT703677.1 (accession no. MT703677.1).

    Not in our library

27. 27.

    Lavi E, Wang Q, Weiss SR, Gonatas NK. 1996. Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus. Virology 221:325–334..

    Not in our library10.1006/viro.1996.0382

28. 28.

    Corver J, Broer R, Van Kasteren P, Spaan W. 2009. Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry. Virol J 6:230–213..

    Not in our library10.1186/1743-422x-6-230

29. 29.

    Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang K-O. 2012. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 86:11754–11762..

    Not in our library10.1128/jvi.01348-12

30. 30.
    Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication · 2020

    Corrected
31. 31.
    Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency · 2020

    No notice
32. 32.

    Krichel B, Falke S, Hilgenfeld R, Redecke L, Uetrecht C. 2020. Processing of the SARS-CoV pp1a/ab nsp7–10 region. Biochem J 477:1009–1019..

    Not in our library10.1042/bcj20200029

33. 33.
    Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease · 2018

    No notice
34. 34.

    Daelemans D, Pauwels R, De Clercq E, Pannecouque C. 2011. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc 6:925–933..

    Not in our library10.1038/nprot.2011.330

35. 35.

    Reid AT, Sutanto EN, Chander-Veerati P, Looi K, Li NF, Iosifidis T, Loo SL, Garratt LW, Kicic A. 2019. Ground zero—the airway epithelium. In Bartlett N, Wark P, Knight D (ed), Rhinovirus infections: rethinking the impact on human health and disease. Academic Press, London, UK.

    Not in our library

36. 36.

    Dittmann M, Koralov SB, Ruggles K. 2020. Data from “Analysis of 3D human airway epithelial cultures by single-cell RNA-seq.” Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166601 (GEO series GSE166601).

    Not in our library

37. 37.
    Novel dynamics of human mucociliary differentiation revealed by single-cell RNA sequencing of nasal epithelial cultures · 2019

    No notice
38. 38.
    Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes · 2021

    No notice
39. 39.

    Greaney AM, Adams TS, Brickman Raredon MS, Gubbins E, Schupp JC, Engler AJ, Ghaedi M, Yuan Y, Kaminski N, Niklason LE. 2020. Platform effects on regeneration by pulmonary basal cells as evaluated by single-cell RNA sequencing. Cell Rep 30:4250–4265.e6..

    Not in our library10.1016/j.celrep.2020.03.004

40. 40.

    Suzuyama N, Katoh M, Takeuchi T, Yoshitomi S, Higuchi T, Asashi S, Yokoi T. 2007. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci 96:1609–1618..

    Not in our library10.1002/jps.20787

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.